Moleculin Biotech, Inc.
At Close: 4:00 PM
Frequently Asked Questions
How did Moleculin Biotech, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, MBRX generated $0 in revenue last quarter, while its costs came in at N/A.
Last quarter, how much Gross Profit did Moleculin Biotech, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Moleculin Biotech, Inc. reported a - Gross Profit for the quarter ended Sep. 2022.
Have MBRX's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. MBRX incurred $9.08 Million worth of Operating Expenses, while it generated -$9.08 Million worth of Operating Income.
How much Net Income has MBRX posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Moleculin Biotech, Inc., the company generated -8.61 Million i Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Moleculin Biotech, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Moleculin Biotech, Inc. as of the end of the last quarter was $50.39 Million.
What are MBRX's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, MBRX had Total Net Receivables of $1.35 Million.
In terms of Total Assets and Current Assets, where did Moleculin Biotech, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of MBRX total $53.49 Million, while the Total Assets are $65.37 Million.
As of the last quarter, how much Total Debt did Moleculin Biotech, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of MBRX's debt was $0 at the end of the last quarter.
What were MBRX's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, MBRX reported total liabilities of $6.96 Million.
How much did MBRX's Working Capital change over the last quarter?
Working Capital Change for MBRX was $1.12 Million over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
MBRX generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. MBRX generated -$20.38 Million of Cash from Operating Activities during its recently reported quarter.
What was MBRX's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. MBRX reported a -$20.51 Million Net Change in Cash in the most recent quarter.